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sions. CONCLUSIONS: When comparing well-matched patients undergoing TKA, 
significantly better clinical and economic outcomes were found using local infiltra-
tion of LB rather than continuous nerve block with elastomeric pumps to manage 
postsurgical pain.
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OBJECTIVES: Erythropoietin has been widely adapted into clinical practice in ortho-
pedic surgery to prevent anemia and ultimately lower the use of allogeneic blood 
transfusions. Its safety and efficacy has been shown in various randomized clini-
cal trials. Questions regarding the cost-effectiveness of this treatment, however, 
have yet to be answered conclusively. Notably, current indication guidelines are 
based on preoperative hemoglobin levels, but do not differentiate between total hip 
arthroplasty (THA) and total knee arthroplasty (TKA). This literature review aims 
at analyzing the cost-effectiveness of preoperative erythropoietin as blood spar-
ing measure in patients undergoing elective orthopedic surgery, specifically THA 
and TKA. Additionally, patient inclusion criteria are analyzed in order to identify 
the potentially most cost-effective patient subgroups, e.g. based on preoperative 
hemoglobin levels, primary or revisional surgery and THA versus TKA. METHODS: 
Systematic literature review. RESULTS: A MEDLINE database search and subsequent 
exclusion of irrelevant or inaccessible papers resulted in the inclusion of 8 research 
articles that at least partially performed a cost-effectiveness or cost-benefit analysis 
of erythropoietin in orthopedic surgery. Four of the studies concluded erythropoi-
etin is not cost-effective, three studies were not able to draw a conclusion based on 
their data, and one study found erythropoietin cost-effective. CONCLUSIONS: We 
found that studies were difficult to compare, with inclusion criteria and compara-
tors varying among studies. Notably, most economic evaluations were substantially 
lacking depth and did not comply with common guidelines for pharmacoeconomic 
research. Although some articles found erythropoietin generally not cost-effec-
tive, their data did suggest otherwise within certain patient subgroups. Patients 
with lower preoperative hemoglobin levels, primary surgery and THA benefitted 
the most from erythropoietin. Additionally, most studies seemed to overestimate 
treatment costs, using outdated prices or neglecting competitively priced biosimi-
lars. Therefore, a more differentiated approach is required to elucidate the cost-
effectiveness of erythropoietin in orthopedic surgery, discriminating between total 
hip and knee arthroplasty.
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OBJECTIVES: The Colombian Health Care System has had a plan with limited ben-
efits, but since 2012, 57 drugs have been added to this plan. This research describes 
the trends of utilization and costs of medications covered by the Agreement 
029/2011 and compare them with those that were contained in the benefits 
plan. METHODS: A descriptive study involving a group of 3.8 million people affili-
ated with the Colombian Health Care System, in 110 cities from July 2011 until June 
2013. The variables were: new medications that were included, comparing them 
with homologous medications that were already in the plan, age, sex, dispensed 
quantities, and monthly billing. The study established the defined daily dosage per 
thousand inhabitants and day (DID), cost per thousand inhabitants and day (CID), 
cost per capita (CPC) and the rate of adoption or replacement medicines. RESULTS: 
The growth in consumption of new medications was 830.0%. The DID grew from 
4.3 to 42.9 with an increase of 905.5%. The medications with the highest growth 
were losartan/hydrochlorothiazide (15723%), esomeprazole (4193%), atorvastatin 
(1402%) and sertraline (298%). There was an increase in costs of US$16.40 in CID, 
which is equivalent to an increase of 61.7% and represents a rise of US$0.49 CPC 
per month. CONCLUSIONS: The consumption behavior of new medications and 
the economic implications for Colombia can be demonstrated. In particular, the 
growth of consumption of medications for chronic diseases can be seen, which 
would represent an increase to the entire population of the country of US$22.6 
million per month.
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OBJECTIVES: As new medications enter the market for rheumatoid arthritis (RA), 
economic evaluations of medications provide critical information for assessing cost 
effectiveness. The study objective was to estimate incremental cost per quality-
adjusted life year (QALY) of tofacitinib 5mg BID, a new treatment for moderate 
to severe RA after inadequate response to methotrexate, compared to available/
recommended treatment strategies as of 2014 using the Canadian 3rd-party-payer 
perspective and lifetime time horizon. METHODS: The cost utility model is an 
individual patient simulation through a Markov-like model. The model compares 
treatment strategies reflecting 2012 Canadian Rheumatology Association recom-
mendations for the pharmacological management of RA. Tofacitinib was included in 
the treatment algorithm similar to the anti-TNFs. Efficacy was measured using the 
continuous variable of Health Assessment Questionnaire Disability Index (HAQ-DI) 
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OBJECTIVES: Guidelines for primary care management of LBP in primary care rec-
ommend an initial period of watchful waiting before referral to PT. Some evidence 
suggests early PT may reduce future health care costs for LBP. This study compared 
LBP-related costs over a 1-year period in patients with acute LBP randomly assigned 
to usual care versus early PT. METHODS: Adults (age 18-60) visiting primary care 
with acute, non-specific LBP were recruited. All participants received advice and 
education about LBP and were randomized to 4 PT sessions or watchful waiting for 
4 weeks. Clinical outcomes and LBP-related costs were collected monthly for 1 year 
after enrollment using online diaries of health care utilization and work loss due to 
LBP. RESULTS: 196 participants were included of which 101 received early PT and 
95 usual care. Mean age was 37.5 years (+10.5) and 106 (54.1%) were female. Mean 
baseline Oswestry disability score was 40.4 (+13.0) and numeric pain rating was 5.0 
(+1.8). There were no differences between treatment groups for these characteristics 
or race/ethnicity, marital status, body mass index, smoking status, or medications 
prescribed at baseline. Repeated measures ANOVA found a significant group * time 
interaction for the outcome of pain (p< 0.028) across 1 year, but by the end of 1 year 
the early PT experienced a mean 0.31 points greater pain relief. Mean total LBP-
related costs over the year were $1,581 for early PT and $915 for usual care (mean 
difference $666, p= 0.067). The incremental cost-effectiveness ratio was $2,149 per 
1 point of pain intensity reduction per patient. CONCLUSIONS: Early PT showed 
small benefits in pain reduction across 1-year. The incremental cost effectiveness 
ratio may exceed willingness to pay thresholds.
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OBJECTIVES: Despite advances in hemostasis techniques, spinal fusion procedures 
result in significant blood loss and are associated with extensive post-surgery com-
plications. This study aimed to evaluate blood loss levels and its role in the economic 
burden of spinal fusion surgery. METHODS: A comprehensive literature review was 
conducted to evaluate the blood loss levels and economic burden of spinal fusion 
procedures for adolescent scoliosis (AS) and adult deformity (AD). In total, 75 articles 
were reviewed to collect blood loss and cost components such as operating (OR) 
time, blood loss, hospital length of stay (LoS), and transfusion needs. Costs of pre-
surgery care, surgical devices, and other surgical consumables were excluded from 
the analysis. RESULTS: Blood loss in spinal fusion surgery was found to be in the 0.6 
- 2.6L range depending on population and clinical setting. Patients required 0.6 to 1.0 
units of transfused blood, with varying levels of red blood cells, plasma, and platelets 
needed. The bulk of the economic burden of spinal fusion was due to utilization of 
hospital resources including OR time, LoS, and management of surgical side infec-
tion (SSI), with transfusion and anesthesia costs also contributing. OR time ranged 
from 2.7 hours in adults to 6.5 hours in adolescents. Post-operation LoS was in the 
3.8 - 8 day range and was strongly correlated with blood loss-related complications. 
Furthermore, with a mean cost of $23,860 per case and an incidence of 5.6%, SSI was 
noted as an uncommon but high-cost risk of spinal fusion. These components of 
economic burden add up to mean per-patient costs of $15,990 for AD patients and 
$12,647 for AS patients. CONCLUSIONS: Although surgeons currently use various 
tactics to manage blood loss during spinal fusion procedures, including electrocautery, 
blood transfusion, and topical hemostatic agents, blood loss and economic burden 
remain significant.
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OBJECTIVES: In response to increasing demand and limited resources, hospitals are 
exploring more efficient methods to perform TKA. The objective of this study was to 
examine the clinical and economic outcomes associated with using local infiltration 
of LB to manage postsurgical pain following TKA. METHODS: This study compared 
134 consecutive patients whose postsurgical pain following TKA was managed using 
local infiltration of LB (study group) to 134 historical patients who received continu-
ous nerve block with elastomeric pumps (control group). Groups were matched on 
clinical and demographic variables, including age, gender, race, and comorbidities, 
and sample size was based on estimated effect sizes. Outcomes examined included 
use of postsurgical opioid and non-opioid analgesics, time to ambulation, distance 
walked, pain scores, adverse effects, length of stay (LOS), discharge status, and total 
hospital costs. RESULTS: Significantly more patients in the study group (22%) were 
able to ambulate on the day of surgery than in the control group (3%) (p< 0.05). The 
study group had more patients discharged in 3 days or less (50%) than the control 
group (19%) (p< 0.05), and had a shorter mean LOS (2.8 ±1.7 days vs. 3.2±1.6 days). 
Total hospital costs were $366 less in the study group ($8,816/patient) than in the 
control group ($9,182/patient), which was mainly attributed to differences in the cost 
of room and board ($1,449 vs. $1,721, p< 0.05). After multivariate regression, adjusted 
cost savings in the study group were $457/patient (p< 0.05). No differences were found 
between in pain scores, opioid analgesic use, adverse events, or 30-day readmis-
